Prevalence of Helicobacter Pylori in symptomatic patients post triple therapy eradication in Jordan

Tarif, Sultan Bin; Gamaz, Anas; Khasawneh, Hayat; Al Shebli, Hussien; Al Sharari, Deifallah

[Home ] [Archive]

International Journal of Medical Investigation

Main Menu

Home

Journal Information

Articles archive

For Authors

For Reviewers

Registration

Contact us

Site Facilities

Editorial Board

Search in website

Receive site information

Volume 4, Issue 2 (June 2015)

Int J Med Invest 2015, 4(2): 249-251

Back to browse issues page

Prevalence of Helicobacter Pylori in symptomatic patients post triple therapy eradication in Jordan

Sultan Bin Tarif ^*

, Anas Gamaz

, Hayat Khasawneh

, Hussien Al Shebli

, Deifallah Al Sharari

Endoscopy unit,King Hussein Medical Center Amman, Jordan

Abstract: (8963 Views)

Background and Objective: Despite the use of triple therapy for H.pylori eradication, significant number of the patients still has same complaint. In view of their complaint and increase number of the studies showed decrease in the cure rate of triple therapy, we look at the prevalence of Helicobacter Pylori (HP) in symptomatic patients post a fourteen days’ course of triple therapy in documented HP gastritis by histopathology. Method and Materials: A retrospective study, which includes one hundred and five patients, whom underwent endoscopies for epigastric pain, from May2014 till February 2015,and have had gastric biopsies that showed chronic active gastritis with presence of HP. Triple eradication therapy in the form of omperazole 20mg BID, amoxicillin 1g BID and clarithromycin 500mg BID was given for 14 days. These patients were selected as they remain symptomatic post eradication therapy. The presence of HP after eradication was confirmed by stool antigen test six weeks after the end of treatment with complete avoidance of antibiotics, proton pump inhibitors and histamine 2 receptor antagonists during this period. Result: The rate of eradication in these symptomatic patients was 61.9%. Failure of eradication was seen in 33.3% of the male group (10 patients) and 40% of the female group (30 patients). Conclusion: Our study showed that triple therapy eradication rate was 61.9%, which is lower than international findings this may be explained by fact that we only screened the symptomatic patient post eradication therapy and not all patients who received the course. Studies on HP sensitivity for antibiotic should be done to guide eradication regimens to reach acceptable eradication rates.

Keywords: Helicobacter Pylori, Triple therapy, Gastritis, Stool Antigen test

Full-Text [PDF 234 kb] (2295 Downloads)

Type of Study: Research | Subject: General

References

1. 1. Zheng Q,Chen WJ,LuH,SunQJ,XiaoSD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.J Dig Dis.21 Oct;11(5):313-8.PMID: 20883428. 2. Karatapanis S, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P,et al. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? Arandomized trial".Acta Gastroenterol Belg. 2011 Sep;74(3):407-12. PMID: 22103045 3. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1255-68. PMID: 2201774. 4. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther. 2012 Feb 6;3(1). PMID: 22408744 5. Loghmari H1, Bdioui F, Bouhlel W, Melki W, Hellara O, Ben Chaabane N,et al. Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults. Tunis Med. 2012 Jan;90(1):31-5. PMID: 22311445 6. Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol. 2009 Nov;25(6):549-56. PMID:19696666. 7. Proença-Modena JL, Acrani GO, Brocchi M. Helicobacter pylori: phenotypes, genotypes and virulence genes. Future Microbiol. 2009 Mar;4(2):223-40. PMID: 19257848. 8. Toyokawa T, Suwaki K, Miyake Y, Nakatsu M, Ando M. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol. 2010 Mar;25(3):544-7. PMID:19817964. 9. Miftahussurur M, Yamaoka Y. Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules. 2015 Apr 8;20(4):6068-6092. PMID: 25856059. 10. Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavía M ,et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacterpylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015 Apr 7. PMID: 25855760. 11. Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A,et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther. 2015 Mar;41(6):581-9. PMID:

Add your comments about this article

Mendeley

Zotero

RefWorks

Tarif S B, Gamaz A, Khasawneh H, Al Shebli H, Al Sharari D. Prevalence of Helicobacter Pylori in symptomatic patients post triple therapy eradication in Jordan. Int J Med Invest 2015; 4 (2) :249-251
URL: http://intjmi.com/article-1-135-en.html

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Volume 4, Issue 2 (June 2015)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4645